# US 2020/0392168 A1 · Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392168 A1
- Document ID: US20200392168A1
- Status: Published application
- Kind: A1
- Application number: 16/908,244
- Filed: 2020-06-22
- Published: 2020-12-17
- Earliest claimed: 2013-05-28
- Assignees: Morphochem Aktiengesellschaft Fur Kombinatorische Chemie
- Applicants: Morphochem Aktiengesellschaft Für Kombinatorische Chemie
- Inventors: Thomas KAPSNER; Axel DALHOFF; Thomas GRAMATTE
- Web page: https://patentgrep.com/patent/US20200392168A1

## CPC

- C07F 9/653: Five-membered rings
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.

## Claims

### Claim at position 1

1-32. (canceled)

### Claim 33

A method for treating a bacterial infection caused by Clostridium difficile, comprising administering to a patient in need thereof a compound, which is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:
or a pharmacologically acceptable salt thereof.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the compound, or a pharmacologically acceptable salt thereof, is administered by an infusion.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of from 0.4 to 3 mg/(kg body weight×h).

### Claim 36 (depends on 35)

The method according to claim 35, wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of from 0.4 to 1.5 mg/(kg body weight×h).

### Claim 37 (depends on 36)

The method according to claim 36, wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of from 0.4 to 0.75 mg/(kg body weight×h).

### Claim 38 (depends on 37)

The method according to claim 37, wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of 0.5 mg/(kg body weight×h).

### Claim 39 (depends on 33)

The method according to claim 33, wherein the compound, or a pharmacologically acceptable salt thereof, is administered over a period of from 20 min to 24 h per day.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the compound, or a pharmacologically acceptable salt thereof, is administered over a period of from 4 h to 12 h per day.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the compound, or a pharmacologically acceptable salt thereof, is administered over a period of 12 h per day.

### Claim 42 (depends on 33)

The method according to claim 33, wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily for a period of up to 10 days.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily for a period of 10 days.

### Claim 44 (depends on 33)

The method according to claim 33, wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily at a dose of 6 mg/kg.

### Claim 45 (depends on 33)

The method according to claim 33, wherein the compound, or a pharmacologically acceptable salt thereof, is a sodium salt of the compound.

### Claim 46 (depends on 33)

The method according to claim 33, wherein the bacterial infection caused by Clostridium difficile is an intestinal disease caused by Clostridium difficile.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the intestinal disease caused by Clostridium difficile is diarrhea, colitis, or pseudomembranous colitis.

### Claim 48 (depends on 33)

The method according to claim 33, wherein the bacterial infection caused by Clostridium difficile is ileus, toxic megacolon, fulminant colitis, colonic perforation or need for colectomy.

### Claim 49

A method for treating an intestinal disease caused by Clostridium difficile, comprising administering to a patient in need thereof a compound, which is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:
or a pharmacologically acceptable salt thereof, wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily at an infusion rate of 0.5 mg/(kg body weight×h) over a period of 12 h per day for a period of 10 days.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the intestinal disease caused by Clostridium difficile is diarrhea, colitis, or pseudomembranous colitis.

### Claim 51 (depends on 49)

The method according to claim 49, wherein the intestinal infection caused by Clostridium difficile is ileus, toxic megacolon, fulminant colitis, colonic perforation or need for colectomy.

### Claim 52 (depends on 49)

The method according to claim 49, wherein the compound, or a pharmacologically acceptable salt thereof, is a sodium salt of the compound.
